showed that EZH2 was over-expressed in HCC tissues and cell lines, and miR-101 could target EZH2 to inhibit HCC progression and increase chemotherapeutic treatment sensitivity (37). This evidence concerns the gene EZH2 and hepatocellular carcinoma.